ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $108,781 | -5.0% | 1,162 | -9.5% | 0.00% | – |
| Q2 2023 | $114,554 | +5.1% | 1,284 | +26.3% | 0.00% | – |
| Q1 2023 | $108,993 | +3.8% | 1,017 | +18.0% | 0.00% | – |
| Q4 2022 | $105,000 | +6.1% | 862 | -9.2% | 0.00% | – |
| Q3 2022 | $99,000 | +22.2% | 949 | +9.0% | 0.00% | – |
| Q2 2022 | $81,000 | +6.6% | 871 | +33.8% | 0.00% | – |
| Q1 2022 | $76,000 | -16.5% | 651 | -3.7% | 0.00% | – |
| Q4 2021 | $91,000 | -71.1% | 676 | -65.9% | 0.00% | -100.0% |
| Q3 2021 | $315,000 | +14.5% | 1,980 | -5.5% | 0.00% | 0.0% |
| Q2 2021 | $275,000 | +1.1% | 2,095 | -0.8% | 0.00% | 0.0% |
| Q1 2021 | $272,000 | -11.7% | 2,112 | +14.7% | 0.00% | 0.0% |
| Q4 2020 | $308,000 | +15.8% | 1,841 | +6.5% | 0.00% | 0.0% |
| Q3 2020 | $266,000 | +28.5% | 1,729 | +23.1% | 0.00% | 0.0% |
| Q2 2020 | $207,000 | +1781.8% | 1,405 | +1264.1% | 0.00% | – |
| Q1 2020 | $11,000 | – | 103 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 11,225,357 | $1,001,863,112 | 18.92% |
| Q Global Advisors, LLC | 195,000 | $17,404 | 12.55% |
| Sofinnova Investments, Inc. | 754,032 | $67,297,356 | 4.41% |
| Avoro Capital Advisors LLC | 3,580,555 | $319,564,534 | 4.34% |
| Finepoint Capital LP | 139,772 | $12,474,651 | 4.32% |
| Spyglass Capital Management LLC | 657,853 | $58,713,380 | 4.24% |
| Saturn V Capital Management LP | 78,442 | $7,000,948 | 3.88% |
| DAFNA Capital Management LLC | 135,212 | $12,067,671 | 3.30% |
| ARS Investment Partners, LLC | 289,860 | $25,870,005 | 3.02% |
| Ghost Tree Capital, LLC | 100,000 | $8,925,000 | 2.95% |